| 1 |
Cheng M, Duzgol C, Kim TH, Ghafoor S, Becker AS, Causa Andrieu PI, Gangai N, Jiang H, Hakimi AA, Vargas HA, Woo S. Sarcomatoid renal cell carcinoma: MRI features and their association with survival. Cancer Imaging 2023;23:16. [PMID: 36793052 DOI: 10.1186/s40644-023-00535-0] [Reference Citation Analysis]
|
| 2 |
Tully KH, Berg S, Paciotti M, Janisch F, Reese SW, Noldus J, Shariat SF, Choueiri T, Müller G, McGregor B, Chang SL, Trinh QD, Mossanen M. The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis. Clin Genitourin Cancer 2023;21:63-8. [PMID: 36517393 DOI: 10.1016/j.clgc.2022.11.015] [Reference Citation Analysis]
|
| 3 |
Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. [PMID: 36174377 DOI: 10.1016/j.ctarc.2022.100640] [Reference Citation Analysis]
|
| 4 |
Zhao X, Yan Y, Dong JH, Liu Z, Zhang HX, Liu C, Ma LL. Influence of Deep Invasive Tumor Thrombus on the Surgical Complexity and Prognosis of Patients With Non-Metastatic Renal Cell Carcinoma Combined With Venous Tumor Thrombus. Front Oncol 2022;12:833780. [PMID: 35223514 DOI: 10.3389/fonc.2022.833780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Mattila KE, Vainio P, Jaakkola PM. Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy. Cancers (Basel) 2022;14:239. [PMID: 35008402 DOI: 10.3390/cancers14010239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 6 |
Candelario N, Geiger C, Flaig T. Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. KCA 2021;5:167-79. [DOI: 10.3233/kca-210126] [Reference Citation Analysis]
|
| 7 |
Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78. [PMID: 33051619 DOI: 10.1038/s41585-020-00382-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 8 |
Yang B, Xia H, Xu C, Lu M, Zhang S, Wang G, Ma L. Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically. BMC Urol 2020;20:14. [PMID: 32070319 DOI: 10.1186/s12894-020-0584-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 9 |
Pecoraro A, Palumbo C, Knipper S, Rosiello G, Luzzago S, Tian Z, Shariat SF, Saad F, Lavallée L, Briganti A, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. Clin Genitourin Cancer 2020;18:e610-8. [PMID: 32173357 DOI: 10.1016/j.clgc.2020.02.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 10 |
Guo C, Zheng W, Zhu W, Yu S, Ding Y, Wu Q, Tang Q, Lu C. Risk factors associated with suicide among kidney cancer patients: A Surveillance, Epidemiology, and End Results analysis. Cancer Med 2019;8:5386-96. [PMID: 31297956 DOI: 10.1002/cam4.2400] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 11 |
Naher S, Padinharakam S, Balakrishnar B, Chua W, Descallar J, Adams D, de Souza P, Harrison M, Lim S. Patterns of Presentation and Treatment Outcomes of Non-clear-cell Renal Cell Carcinoma and Sarcomatoid Renal Cell Carcinoma Patients in 2 Tertiary Referral Centers in Sydney, Australia. Clin Genitourin Cancer 2019;17:e565-9. [PMID: 30935815 DOI: 10.1016/j.clgc.2019.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 12 |
Alevizakos M, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ. Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. Clin Genitourin Cancer 2019;17:e447-53. [PMID: 30799129 DOI: 10.1016/j.clgc.2019.01.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 13 |
Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. World J Urol 2019;37:115-23. [PMID: 29858701 DOI: 10.1007/s00345-018-2355-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 14 |
Korenbaum C, Pierard L, Thiéry A, Story F, Lindner V, Lang H, Kurtz J, Barthélémy P. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience. Clinical Genitourinary Cancer 2018;16:e577-86. [DOI: 10.1016/j.clgc.2017.12.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 15 |
Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer 2017:S1558-7673(17)30238-0. [PMID: 28870517 DOI: 10.1016/j.clgc.2017.07.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
